24/02/2026 – AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS) Download PDF Category: 2026By Alexis BERNARD24 February 2026 Partager cet article Share on LinkedInShare on LinkedIn Share on XShare on X Share on FacebookShare on Facebook Share on WhatsAppShare on WhatsApp Author: Alexis BERNARD Post navigationPreviousPrevious post:FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®NextNext post:Update on clinical development programRelated PostsAB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026AB Science announces the successful completion of a EUR 2.3 million private placement1 July 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs10 July 2026
AB Science’s Board of Directors is restructuring its governance to usher in a new phase in the company’s development8 July 2026
